Tevogen Bio, a clinical stage biotechnology company specializing in immunotherapies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 11,191,827 which significantly reinforces Tevogen’s intellectual property position in use of SARS-CoV-2 specific Cytotoxic CD8+ T Lymphocytes (CTL) immunotherapy for treatment of COVID-19.
“The issuance of a patent that covers our method of preparing COVID-19 peptide specific T cells, and methods of treating COVID-19 using our CTL therapy is a major milestone for Tevogen Bio,” said Tevogen CEO Ryan Saadi, M.D., M.P.H.
“COVID-19 is a mutation-prone RNA virus, and we are already experiencing variants such as Omicron with worrisome immune escape potential to evade our current vaccines. Moreover, Omicron appears to have a high degree of transmissibility,” said Dr. Neal Flomenberg, MD, chairman of Tevogen’s Scientific Advisory Board. “Our Emergency Departments remain very busy and hospitalization rates remain concerningly high. One virtue of our CTLs recognizing multiple targets spread across the entire viral genome is that this helps blunt the impact of mutations. Additionally, our therapeutic targets are not affected in the Delta variant and appear preserved in the Omicron variant as well,” Dr. Flomenberg added.
The granted patent covers Tevogen’s investigational allogeneic SARS-CoV-2-specific Cytotoxic CD8+ T Lymphocytes (CTL) therapy, TVGN-489, for high-risk COVID-19 patients. The product is currently undergoing a proof of concept clinical trial at Thomas Jefferson University in Philadelphia.
TVGN-489 is a highly purified, SARS-CoV-2-specific cytotoxic CD8+ T lymphocyte product, which detects targets spread across the entire viral genome. These targeted CTLs are expected to recognize and kill off virally infected cells, allowing the body to replace them with healthy, uninfected cells. TVGN-489 has already demonstrated strong antiviral activity against SARS-CoV-2 in preclinical studies.
About Tevogen Bio
Tevogen Bio is driven by a team of distinguished scientists and highly experienced biopharmaceutical leaders who have successfully developed and commercialized multiple franchises. In collaboration with key strategic partners, the company moved its lead product from discovery to clinical phase within 12 months of inception, shaving years off the industry’s standard for drug development timelines.
Tevogen’s leadership believes that affordable personalized immunotherapies are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation in the post-pandemic world. The company’s breakthrough technology overcomes traditional barriers to the broad application of targeted T-cell therapies by revolutionizing speed to patient access and achieving unmatched product purity. Tevogen’s focus on organizational and manufacturing efficiency is central to its highly successful biopharma business model and supports its goal to make personalized immunotherapies accessible to the masses for the first time. Tevogen Bio’s research pipeline includes targeted CD8+ T lymphocyte therapeutics for the treatment of common cancers (NSCLC, cervical cancer), as well as serious and difficult to eradicate viral infections (Hepatitis B).
Forward Looking Statements
This press release contains certain forward-looking statements relating to Tevogen Bio™ Inc.’s (the “Company”) development and patient access of its innovations in infectious diseases and oncology. These statements are based on management’s current expectations and beliefs as of the date of this release and are subject to a number of factors which involve known and unknown risks, delays, uncertainties and other factors not under the company’s control which may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations implied by these forward-looking statements. In any forward-looking statement in which the Company expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These factors include results of current or pending clinical trials, risks associated with intellectual property protection, financial projections, sales, pricing and actions by the FDA/EMA. The Company undertakes no obligation to update the forward-looking statements or any of the information in this release, or provide additional information, and expressly disclaims any and all liability and make no representations or warranties in connection herewith or with respect to any omissions herefrom.
Corporate Communications Lead